In the Era of BCR-ABL1 Inhibitors, Are We Closing the Survival Gap Between Allogeneic Hematopoietic Cell Transplantation and Chemotherapy for Ph+ ALL in First Complete Remission?
Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2018.02.011
Full Text
Open PDFAbstract
Available in full text
Date
April 1, 2018
Authors
Publisher
Elsevier BV